<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-Jun</td>
<td>12:00 - 12:05 AM</td>
<td>Immunotherapeutic Modalities</td>
<td>Checkpoint blockade-induced autoimmunity: Lessons from mouse models of type 1 diabetes</td>
<td>Tijana Martinov, PhD Postdoctoral Fellow, Laboratory of Dr. Philip Greenberg, Fred Hutchinson Cancer Research Center, Scholar of the Parker Institute for Cancer Immunotherapy</td>
</tr>
<tr>
<td>3-Jun</td>
<td>12:00 - 12:05 AM</td>
<td>Development and Clinical Applications of Cancer Immunotherapies</td>
<td>Clinical Development of Immunotherapy in Urothelial Cancer</td>
<td>Scot Niglio, MD Assistant Research Physician, National Institutes of Health, National Cancer Institute, Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology</td>
</tr>
<tr>
<td>3-Jun</td>
<td>12:00 - 12:05 AM</td>
<td>Immunotherapeutic Modalities</td>
<td>Deciphering the function of B cells in human cancer</td>
<td>Tullia C. Bruno, PhD Assistant Professor of Immunology, University of Pittsburgh, Hillman Cancer Center</td>
</tr>
<tr>
<td>3-Jun</td>
<td>12:00 - 12:05 AM</td>
<td>Latest Trends in Immuno-Oncology</td>
<td>Define challenges of tissue-based biomarker development for Immuno-Oncology Therapy</td>
<td>Houssein Sater, MD Physician scientist at NCI (National Cancer Institute)</td>
</tr>
<tr>
<td>3-Jun</td>
<td>12:00 - 12:05 AM</td>
<td>Latest Trends in Immuno-Oncology</td>
<td>Microenvironment on Demand: A breakthrough technology for personalized cell therapy discoveries</td>
<td>Maithreyan Srinivasan Chief Scientific Officer, Scribe Biosciences</td>
</tr>
<tr>
<td>3-Jun</td>
<td>12:00 - 12:05 AM</td>
<td>Latest Trends in Immuno-Oncology</td>
<td>Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins</td>
<td>Shannon K. Oda, PhD Principal Investigator, Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Washington School of Medicine</td>
</tr>
<tr>
<td>3-Jun</td>
<td>12:00 - 12:05 AM</td>
<td>Immunotherapeutic Modalities</td>
<td>Primary and Acquired Resistance to Cancer Immunotherapy</td>
<td>Leonardo Nissola, MD Clinical Scientist, The Parker Institute for Cancer Immunotherapy, and Former Medical Oncology Fellow at the University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Date</td>
<td>Time</td>
<td>Session Title</td>
<td>Presentation Title</td>
<td>Presenter(s)</td>
</tr>
<tr>
<td>-------</td>
<td>---------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 3-Jun | 06:00 - 07:00 AM | Immunotherapeutic Modalities                  | Keynote Presentation: Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment | Sumit K. Subudhi, MD, PhD  
Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center |
| 3-Jun | 07:00 - 08:00 AM | Immunotherapeutic Modalities                  | High throughput biomarker profiling for immuno-oncology research using MILLIPLEX® assays               | Jenny Koenitzer, PhD  
Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA  
Yan Nikhamin, MS, MBA  
Biomarkers & Cytometry Specialist MilliporeSigma |
| 3-Jun | 08:00 - 09:00 AM | Development and Clinical Applications of Cancer Immunotherapies | Keynote Presentation: It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology | Alexander David Borowsky, MD  
Professor, Pathology and Laboratory Medicine, Center for Immunology and Infectious Disease and UC Davis Comprehensive Cancer Center |
| 3-Jun | 09:30 - 10:30 AM | Latest Trends in Immuno-Oncology              | Keynote Presentation: The Importance of Tissue Chemistry in Immunity-Oncology                           | Thomas M. Grogan, MD  
Professor Emeritus of Pathology, University of Arizona; Founder and Chief Scientific Advisor Emeritus, Ventana Medical Systems, Inc., a division of Roche |
| 3-Jun | 11:00 - 12:00 PM | Immunotherapeutic Modalities                  | Keynote Presentation: Combinatorial Approaches to Immunotherapy: Melanoma as the Example              | Stephen Hodi, MD  
Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School |
| 3-Jun | 12:00 - 01:00 PM | Latest Trends In Immuno-Oncology              | How multiplexed imaging reveals key insights into the tumor microenvironment to inform treatment and improve outcomes | Paul Goodwin  
President, The Histochemical Society; Science Director for Cytiva  
Fiona Ginty  
Technology Manager for Biosciences, GE Research Center  
Prachi Bogetto  
Diagnostics Segment Leader/Marketing Leader Cell Analysis, Cytiva |
| 3-Jun | 12:00 - 01:00 PM | Development and Clinical Applications of Cancer Immunotherapies | Single cell multiomic analysis of T-cell exhaustion                                                  | Pratip K. Chattopadhyay, PhD  
Director, Precision Immunology Laboratory, Perlmutter Cancer Center, NYU Langone Health |
| 3-Jun | 01:00 - 02:00 PM | Immunotherapeutic Modalities                  | Gene manipulation in primary human immune cells: Successful strategies and applications for CRISPRKo, RNAi and beyond | Verena Brucklacher-Waldert, PhD  
PhD in Neuroimmunology from the University of Tübingen, Germany, Manager Immunology Screening Services at Horizon Discovery |
| 3-Jun  | 02:00 - 03:00 PM | Development and Clinical Applications of Cancer Immunotherapies | Dynamic Live Cell Imaging of Adherent and Immune Cells using CellASIC® ONIX2 Microfluidic Platform | Jun Park, PhD  
Senior Scientist, MilliporeSigma |
|--------|----------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------|
| 3-Jun  | 03:00 - 04:00 PM | Immunotherapeutic Modalities                                  | The roles of neoantigen peptides in personalized medicine                                       | Samantha Zaroff, PhD  
Product Manager of Neoantigen Peptide Services at GenScript |
| 3-Jun  | 04:00 - 05:00 PM | Microfluidic precision autostainer for fast multiplexed TSA-based immunofluorescence | Spatial Mapping of Gene Expression in Tumors using the RNAscope™ Technology                      | Alexandre Kehren, M.Sc.  
Application Development Engineer  
Anushka Dikshit, PhD  
Application Scientist - Advanced Cell Diagnostics |